Sylvain Lehmann

List of Publications by Year
in descending order

268	13,645	18482 62	27406 106
papers	citations	h-index	g-index

299	299	299	14104
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 1-18.	6.1	14
2	Hypoxemia increases blood-brain barrier permeability during extreme apnea in humans. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1120-1135.	4.3	18
3	Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldtâ€“Jakob disease in clinical practice. Journal of Neural Transmission, 2022, 129, 133-139.	2.8	6
4	The AÎ²1â€“42/AÎ²1â€“40 ratio in CSF is more strongly associated to tau markers and clinical progression than AÎ²1â€“42 alone. Alzheimer's Research and Therapy, 2022, 14, 20.	6.2	18
5	Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. Alzheimer's and Dementia, 2022, 18, 2537-2550.	0.8	21
6	Deciphering Black Extrinsic Tooth Stain Composition in Children Using Metaproteomics. ACS Omega, 2022, 7, 8258-8267.	3.5	5
7	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Journal of Neural Transmission, 2022, 129, 231-237.	2.8	7
8	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
9	Immunoassay and Mass Spectrometry Methods for Tau Protein Quantification in the Cerebrospinal Fluid. Neuromethods, 2021, , 71-85.	0.3	0
10	Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial. Critical Care, 2021, 25, 62.	5.8	28
11	Sensitive protein misfolding cyclic amplification of sporadic Creutzfeldtâ€“Jakob disease prions is strongly seed and substrate dependent. Scientific Reports, 2021, 11, 4058.	3.3	10
12	Tau protein in cerebrospinal fluid: a novel biomarker of the time of death?. International Journal of Legal Medicine, 2021, 135, 2081-2089.	2.2	7
13	The potential impact of salivary peptides in periodontitis. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 479-492.	6.1	14
14	NFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline. Scientific Reports, 2021, 11, 10283.	3.3	11
15	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214.	1.9	30
16	Cytokines as new biomarkers of skin wound vitality. International Journal of Legal Medicine, 2021, 135, 2537-2545.	2.2	14
17	Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. International Journal of Cancer, 2021, 149, 1605-1618.	5.1	8
18	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimerâ€™s disease in adults with Down syndrome. Nature Communications, 2021, 12, 4304.	12.8	33

#	Article	IF	Citations
19	Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients. Bioanalysis, 2021, 13, 1029-1035.	1.5	6
20	Association of Apolipoprotein E É›4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. JAMA Neurology, 2021, 78, 937.	9.0	32
21	Deconstructing Alzheimerâ€™s Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?. International Journal of Molecular Sciences, 2021, 22, 8769.	4.1	12
22	Concussion history in rugby union players is associated with depressed cerebrovascular reactivity and cognition. Scandinavian Journal of Medicine and Science in Sports, 2021, 31, 2291-2299.	2.9	7
23	Variation of human salivary alpha-amylase proteoforms in three stimulation models. Clinical Oral Investigations, 2020, 24, 475-486.	3.0	7
24	Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimerâ€™s disease: Where do we stand?. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 99-113.	6.1	24
25	Cerebrospinal fluid A beta 1â€“40 peptides increase in Alzheimerâ€™s disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research and Therapy, 2020, 12, 123.	6.2	33
26	Hepcidin and ferritin levels in restless legs syndrome: a caseâ€“control study. Scientific Reports, 2020, 10, 11914.	3.3	21
27	The importance of an integrated genotype-phenotype strategy to unravel the molecular bases of titinopathies. Neuromuscular Disorders, 2020, 30, 877-887.	0.6	18
28	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarkerâ€“based caseâ€“control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
29	Editorial: Proteomics as a Tool for Biomarker and Drug Target Discovery: Improving the Diagnosis and Treatment of Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2020, 12, 232.	3.4	1
30	MALDIâ€TOF IPâ€MS quantification of plasma amyloid peptides in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e047112.	0.8	2
31	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911.	2.6	9
32	Gravitational Transitions Increase Posterior Cerebral Perfusion and Systemic Oxidative-nitrosative Stress: Implications for Neurovascular Unit Integrity. Neuroscience, 2020, 441, 142-160.	2.3	9
33	Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimerâ€™s disease and PET amyloid-positive patient identification. Alzheimer's Research and Therapy, 2020, 12, 26.	6.2	138
34	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
35	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet, The, 2020, 395, 1988-1997.	13.7	164
36	Efficient extraction of intact HSA-AÎ² peptide complexes from sera: Toward albuminome biomarker identification. Talanta, 2020, 216, 121002.	5.5	4

#	Article	IF	Citations
37	Correlation between Bioassay and Protein Misfolding Cyclic Amplification for Variant Creutzfeldt-Jakob Disease Decontamination Studies. MSphere, 2020, 5, .	2.9	20
38	Peripheral Blood and Salivary Biomarkers of Bloodâ€“Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts. Frontiers in Neurology, 2020, 11, 577312.	2.4	36
39	Title is missing!. , 2020, 17, e1003289.		0
40	Title is missing!. , 2020, 17, e1003289.		0
41	Title is missing!. , 2020, 17, e1003289.		0
42	Title is missing!. , 2020, 17, e1003289.		0
43	Title is missing!. , 2020, 17, e1003289.		0
44	Title is missing!. , 2020, 17, e1003289.		0
45	Title is missing!. , 2020, 17, e1003289.		0
46	In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid. Analytical Chemistry, 2019, 91, 15500-15508.	6.5	6
47	A Clinico-Radiological Study of Cerebral Amyloid Angiopathy-Related Inflammation. Cerebrovascular Diseases, 2019, 48, 38-44.	1.7	19
48	Generation of induced pluripotent stem cells (IRMBi001-A) from an Alzheimer's disease patient carrying a G217D mutation in the PSEN1 gene. Stem Cell Research, 2019, 34, 101381.	0.7	7
49	SILK studies â€" capturing the turnover of proteins linked to neurodegenerative diseases. Nature Reviews Neurology, 2019, 15, 419-427.	10.1	37
50	Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology. Handbook of Behavioral Neuroscience, 2019, 29, 173-190.	0.7	0
51	Biochemical markers of time since death in cerebrospinal fluid: A first step towardsâ€œForensomicsâ€. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 274-286.	6.1	8
52	Advantages and disadvantages of the use of the CSF Amyloid Î² (AÎ²) 42/40 ratio in the diagnosis of Alzheimerâ€™s Disease. Alzheimer's Research and Therapy, 2019, 11, 34.	6.2	325
53	Intact Protein Analysis by LC-MS for Characterizing Biomarkers in Cerebrospinal Fluid. Methods in Molecular Biology, 2019, 1959, 163-172.	0.9	0
54	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82

#	Article	IF	Citations
55	Dental stem cells as a promising source for cell therapies in neurological diseases. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 170-181.	6.1	9
56	Cell-based therapy against prion diseases. Current Opinion in Pharmacology, 2019, 44, 8-14.	3.5	4
57	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Clinica Chimica Acta, 2019, 490, 98-101.	1.1	17
58	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Annals of Neurology, 2019, 85, 74-83.	5.3	18
59	Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. Multiple Sclerosis Journal, 2019, 25, 669-677.	3.0	28
60	The prognostic value of theÂTau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer, 2019, 19, 110.	2.6	20
61	Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. Alzheimer's and Dementia, 2018, 14, 858-868.	0.8	103
62	Nano-flow vs standard-flow: Which is the more suitable LC/MS method for quantifying hepcidin-25 in human serum in routine clinical settings?. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1086, 110-117.	2.3	6
63	Association between serum hepcidin level and restless legs syndrome. Movement Disorders, 2018, 33, 618-627.	3.9	25
64	Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation. Journal of Alzheimer's Disease, 2018, 61, 1107-1117.	2.6	14
65	Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples. Bioanalysis, 2018, 10, 35-45.	1.5	12
66	Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimerâ€™s disease at the prodromal stage. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 467-475.	1.9	30
67	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	6.2	40
68	Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches. Data in Brief, 2018, 18, 1013-1021.	1.0	12
69	Data from a targeted proteomics approach to discover biomarkers in saliva for the clinical diagnosis of periodontitis. Data in Brief, 2018, 18, 294-299.	1.0	13
70	Towards a routine application of Top-Down approaches for label-free discovery workflows. Journal of Proteomics, 2018, 175, 12-26.	2.4	17
71	Neuropathology of iatrogenic Creutzfeldtâ€“Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology. Acta Neuropathologica, 2018, 135, 201-212.	7.7	71
72	Sample Pooling and Inflammation Linked to the False Selection of Biomarkers for Neurodegenerative Diseases in Topâ€“Down Proteomics: A Pilot Study. Frontiers in Molecular Neuroscience, 2018, 11, 477.	2.9	20

#	Article	IF	Citations
73	Impact of biological matrix on inflammatory protein biomarker quantification based on targeted mass spectrometry. Bioanalysis, 2018, 10, 1383-1399.	1.5	5
74	Hepcidin: immunoanalytic characteristics. Annales De Biologie Clinique, 2018, 76, 705-715.	0.1	0
75	Interlaboratory validation of cerebrospinal fluid Î±â€synuclein quantification in the diagnosis of sporadic Creutzfeldtâ€Jakob disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 461-470.	2.4	7
76	Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides AÎ²1â€“42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 297.	3.4	10
77	Diagnosis of Methionine/Valine Variant Creutzfeldt-Jakob Disease by Protein Misfolding Cyclic Amplification. Emerging Infectious Diseases, 2018, 24, 1364-1366.	4.3	27
78	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurology, The, 2018, 17, 860-869.	10.2	140
79	What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?. Bioanalysis, 2018, 10, 723-735.	1.5	12
80	Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 346-358.	6.1	9
81	Alzheimerâ€™s Disease: Advances in Drug Development. Journal of Alzheimer's Disease, 2018, 65, 3-13.	2.6	45
82	Relevance of AÎ²42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. Frontiers in Aging Neuroscience, 2018, 10, 138.	3.4	59
83	Cerebral Amyloid Angiopathy and Cerebral Amyloid Angiopathy-Related Inflammation: Comparison of Hemorrhagic and DWI MRI Features. Journal of Alzheimer's Disease, 2018, 64, 1113-1121.	2.6	17
84	Lithium as a disease-modifying agent for prion diseases. Translational Psychiatry, 2018, 8, 163.	4.8	9
85	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700.	1.4	5
86	Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?. Clinica Chimica Acta, 2017, 467, 51-58.	1.1	29
87	Characterizing Deep White Matter Hyperintensities in Patients with Symptomatic Isolated Cortical Superficial Siderosis. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 465-469.	1.6	1
88	Quantification of hepcidin-25 in human cerebrospinal fluid using LCâ€“MS/MS. Bioanalysis, 2017, 9, 337-347.	1.5	12
89	Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases. Annales De Biologie Clinique, 2017, 75, 9-18.	0.1	3
90	Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. Neurobiology of Aging, 2017, 53, 59-66.	3.1	76

#	Article	IF	Citations
91	Impurity determination for hepcidin by liquid chromatography-high resolution and ion mobility mass spectrometry for the value assignment of candidate primary calibrators. Analytical and Bioanalytical Chemistry, 2017, 409, 2559-2567.	3.7	16
92	Clinical perspectives of dried blood spot protein quantification using mass spectrometry methods. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 173-184.	6.1	19
93	Comparison of HbA1c detection in whole blood and dried blood spots using an automated ion-exchange HPLC system. Bioanalysis, 2017, 9, 427-434.	1.5	14
94	Isolation of Exosomes and Microvesicles from Cell Culture Systems to Study Prion Transmission. Methods in Molecular Biology, 2017, 1545, 153-176.	0.9	25
95	Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial. Anaesthesia, Critical Care & Pain Medicine, 2017, 36, 391-396.	1.4	9
96	Multicenter Analytical Validation of AÎ²40 Immunoassays. Frontiers in Neurology, 2017, 8, 310.	2.4	10
97	Looking for new biomarkers of skin wound vitality with a cytokine-based multiplex assay: preliminary study. Annales De Biologie Clinique, 2017, 75, 53-60.	0.1	3
98	Reform of the outside nomenclature biomedical tests in France: a two year review. Annales De Biologie Clinique, 2017, 75, 365-365.	0.1	0
99	Editorial: Biomarkers of Alzheimerâ€™s Disease: The Present and the Future. Frontiers in Neurology, 2016, 7, 158.	2.4	16
100	Rapid and Highly Sensitive Detection of Variant Creutzfeldt - Jakob Disease Abnormal Prion Protein on Steel Surfaces by Protein Misfolding Cyclic Amplification: Application to Prion Decontamination Studies. PLoS ONE, 2016, 11, e0146833.	2.5	24
101	Cerebrospinal Fluid Alzheimerâ€™s Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis. Journal of Alzheimer's Disease, 2016, 54, 1291-1295.	2.6	16
102	From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Scientific Reports, 2016, 6, 25162.	3.3	36
103	Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimerâ€™s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2016, 51, 1033-1043.	2.6	104
104	O1â€05â€04: PROFILING OF INTACT PROTEINS IN THE CSF OF ALZHEIMERâ€™S DISEASE PATIENTS USING TOP DOWN CLINICAL PROTEOMICS (TDCP): A NEW APPROACH GIVING ACCESS TO ISOFORM SPECIFIC INFORMATION OF NEURODEGENERATIVE BIOMARKERS. Alzheimer's and Dementia, 2016, 12, P183.	0.8	1
105	Cerebrospinal Fluid Alzheimerâ€™s Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation. Journal of Alzheimer's Disease, 2016, 50, 759-764.	2.6	23
106	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	2.6	18
107	Proteomic profile of cerebrospinal fluid in patients with multiple sclerosis using two dimensional gel electrophoresis. British Journal of Biomedical Science, 2016, 73, 143-146.	1.3	4
108	Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing. Clinica Chimica Acta, 2016, 454, 33-38.	1.1	19

#	Article	IF	Citations
109	Amyloid imaging by 18F-florbetaben PET in a patient with isolated microbleeds and leukoencephalopathy. Acta Neurologica Belgica, 2016, 116, 623-625.	1.1	0
110	Absolute quantification of 35 plasma biomarkers in human saliva using targeted MS. Bioanalysis, 2016, 8, 43-53.	1.5	22
111	Human S100A10 plays a crucial role in the acquisition of the endometrial receptivity phenotype. Cell Adhesion and Migration, 2016, 10, 282-298.	2.7	32
112	Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. Journal of Proteome Research, 2016, 15, 667-676.	3.7	91
113	Quiescin-sulfhydryl oxidase inhibits prion formation in vitro. Aging, 2016, 8, 3419-3429.	3.1	2
114	MACVIA-LR (FIGHTING CHRONIC DISEASES FOR ACTIVE AND HEALTHY AGEING IN LANGUEDOC-ROUSSILLON): A SUCCESS STORY OF THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING. Journal of Frailty & Aging,the, 2016, 5, 1-9.	1.3	8
115	O5-05-04: Large scale proteomics exploration of human cerebrospinal fluid (CSF) in Alzheimer's disease patients using stable isotope labeling amino acid in vivo (SILAV). , 2015, 11, P326-P326.		0
116	Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimerâ€™s disease. Clinical Chemistry and Laboratory Medicine, 2015, 53, e175-7.	2.3	1
117	Lateâ€onset behavioral variant of frontotemporal lobar degenerationÂversus Alzheimer's disease: Interest of cerebrospinal fluidÂbiomarkerÂratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 371-379.	2.4	13
118	Cerebrospinal fluid amyloid-Î² 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer's Research and Therapy, 2015, 7, 30.	6.2	101
119	Stable Isotope Labeling by Amino acidin Vivo(SILAV): a new method to explore protein metabolism. Rapid Communications in Mass Spectrometry, 2015, 29, 1917-1925.	1.5	10
120	Central Nervous System and Peripheral Inflammatory Processes in Alzheimerâ€™s Disease: Biomarker Profiling Approach. Frontiers in Neurology, 2015, 6, 181.	2.4	44
121	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	2.4	36
122	Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry. Frontiers in Neuroscience, 2015, 9, 302.	2.8	34
123	Efficient inhibition of infectious prions multiplication and release by targeting the exosomal pathway. Cellular and Molecular Life Sciences, 2015, 72, 4409-4427.	5.4	47
124	What is the potential of dried matrix spot sampling for cerebrospinal fluid analysis?. Bioanalysis, 2015, 7, 2849-2851.	1.5	1
125	Operational definition of Active and Healthy Ageing (AHA): A conceptual framework. Journal of Nutrition, Health and Aging, 2015, 19, 955-960.	3.3	85
126	Developmental determinants in non-communicable chronic diseases and ageing. Thorax, 2015, 70, 595-597.	5.6	45

#	Article	IF	Citations
127	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
128	Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1251-1261.	3.0	131
129	Operative definition of active and healthy ageing (AHA): Meeting report. Montpellier October 20â€“21, 2014. European Geriatric Medicine, 2015, 6, 196-200.	2.8	18
130	Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia, 2015, 29, 1084-1091.	7.2	70
131	Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?. Alzheimer's and Dementia, 2015, 11, 1125-1126.	0.8	8
132	Quantitative detection of amyloid-Î² peptides by mass spectrometry: state of the art and clinical applications. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1483-93.	2.3	30
133	Prion strains are differentially released through the exosomal pathway. Cellular and Molecular Life Sciences, 2015, 72, 1185-1196.	5.4	46
134	Systemic Delivery of siRNA Down Regulates Brain Prion Protein and Ameliorates Neuropathology in Prion Disorder. PLoS ONE, 2014, 9, e88797.	2.5	16
135	Hypocretin and brain ÃŽÂ²-amyloid peptide interactions in cognitive disorders and narcolepsy. Frontiers in Aging Neuroscience, 2014, 6, 119.	3.4	43
136	Prion diseases and adult neurogenesis: How do prions counteract the brain's endogenous repair machinery?. Prion, 2014, 8, 240-246.	1.8	11
137	A diagnostic scale for Alzheimerâ€™s disease based on cerebrospinal fluid biomarker profiles. Alzheimer's Research and Therapy, 2014, 6, 38.	6.2	44
138	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
139	Development and validation of dried matrix spot sampling for the quantitative determination of amyloid Î² peptides in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2014, 52, 649-55.	2.3	8
140	An innovative biologic recycling process of leukoreduction filters to produce active human antimicrobial peptides. Transfusion, 2014, 54, 1332-1339.	1.6	6
141	Relationship between genome and epigenome - challenges and requirements for future research. BMC Genomics, 2014, 15, 487.	2.8	24
142	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. EuPA Open Proteomics, 2014, 3, 60-67.	2.5	19
143	Initial Memory Deficit Profiles in Patients with a Cerebrospinal Fluid Alzheimer's Disease Signature. Journal of Alzheimer's Disease, 2014, 41, 1109-1116.	2.6	11
144	O1-09-02: DETECTION AND QUANTIFICATION OF THE TAU PROTEIN AND ITS ISOFORMS IN THE CSF OF ALZHEIMER'S DISEASE PATIENTS USING MASS SPECTROMETRY. , 2014, 10, P147-P147.		0

#	Article	IF	Citations
145	Systems Medicine Approaches for the Definition of Complex Phenotypes in Chronic Diseases and Ageing. From Concept to Implementation and Policies. Current Pharmaceutical Design, 2014, 20, 5928-5944.	1.9	63
146	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiology of Disease, 2013, 54, 486-491.	4.4	14
147	Biomarkers of Alzheimer's disease: The present and the future. Revue Neurologique, 2013, 169, 719-723.	1.5	12
148	Comparative analysis of protein expression of three stem cell populations: Models of cytokine delivery system in vivo. International Journal of Pharmaceutics, 2013, 440, 72-82.	5.2	42
149	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimer's and Dementia, 2013, 9, 406-413.	0.8	63
150	Prion Replication Occurs in Endogenous Adult Neural Stem Cells and Alters Their Neuronal Fate: Involvement of Endogenous Neural Stem Cells in Prion Diseases. PLoS Pathogens, 2013, 9, e1003485.	4.7	27
151	Performance evaluation of human cytokines profiles obtained by various multiplexed-based technologies underlines a need for standardization. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1385-93.	2.3	24
152	Current and future use of â€œdried blood spotâ€•analyses in clinical chemistry. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1897-1909.	2.3	102
153	Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clinical Chemistry and Laboratory Medicine, 2013, 51, 919-35.	2.3	47
154	Impact of the 2008â€“2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. Journal of Alzheimer's Disease, 2013, 34, 297-305.	2.6	51
155	Recombinant Human Prion Protein Inhibits Prion Propagation in vitro. Scientific Reports, 2013, 3, 2911.	3.3	27
156	From â€œClinical Proteomicsâ€•to â€œClinical Chemistry Proteomicsâ€• considerations using quantitative mass-spectrometry as a model approach. Clinical Chemistry and Laboratory Medicine, 2012, 50, 235-42.	2.3	7
157	Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis. Clinical Chemistry, 2012, 58, 787-789.	3.2	50
158	Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. Journal of Neurology, 2012, 259, 2429-2433.	3.6	65
159	Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes. Journal of Alzheimer's Disease, 2012, 31, 13-20.	2.6	94
160	Transcriptomic and proteomic analyses of human endometrial receptivity under natural cycle. Fertility and Sterility, 2012, 98, S226.	1.0	0
161	Recommendations to standardize preanalytical confounding factors in Alzheimerâ€™s and Parkinsonâ€™s disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	1.4	280
162	Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes and Development, 2011, 25, 2248-2253.	5.9	444

#	Article	IF	Citations
163	Decreased sAÎ²PPÎ², AÎ²38, and AÎ²40 Cerebrospinal Fluid Levels in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2011, 26, 553-563.	2.6	65
164	Stem Cell Therapy Extends Incubation and Survival Time in Prion-Infected Mice in a Time Windowâ€“Dependant Manner. Journal of Infectious Diseases, 2011, 204, 1038-1045.	4.0	23
165	HEPES inhibits the conversion of prion protein in cell culture. Journal of General Virology, 2011, 92, 1244-1250.	2.9	4
166	Oligomeric-Induced Activity by Thienyl Pyrimidine Compounds Traps Prion Infectivity. Journal of Neuroscience, 2011, 31, 14882-14892.	3.6	18
167	Two Dimensional Gel Electrophoresis Analysis of Mesenchymal Stem Cells. Methods in Molecular Biology, 2011, 698, 431-442.	0.9	3
168	Production of a monoclonal antibody, against human Î±-synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the Î±-synuclein locus. Journal of Neuroscience Methods, 2010, 192, 268-276.	2.5	11
169	Standard Preanalytical Coding for Biospecimens: Defining the Sample PREanalytical Code. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1004-1011.	2.5	166
170	Proteomic consequences of expression and pathological conversion of the prion protein in inducible neuroblastoma N2a cells. Prion, 2010, 4, 292-301.	1.8	13
171	Correlations between soluble Î±/Î² forms of amyloid precursor protein and AÎ²38, 40, and 42 in human cerebrospinal fluid. Brain Research, 2010, 1357, 175-183.	2.2	69
172	Human Biospecimen Research: Experimental Protocol and Quality Control Tools. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1017-1025.	2.5	103
173	New hospital disinfection processes for both conventional and prion infectious agents compatible with thermosensitive medical equipment. Journal of Hospital Infection, 2009, 72, 342-350.	2.9	33
174	Comparative proteomic analysis of human mesenchymal and embryonic stem cells: Towards the definition of a mesenchymal stem cell proteomic signature. Proteomics, 2009, 9, 223-232.	2.2	82
175	Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: The more the better?. Journal of Proteomics, 2009, 72, 945-951.	2.4	89
176	Prion Protein Expression and Processing in Human Mononuclear Cells: The Impact of the Codon 129 Prion Gene Polymorphism. PLoS ONE, 2009, 4, e5796.	2.5	4
177	The Role of the Prion Protein in the Molecular Basis for Synaptic Plasticity and Nervous System Development. Journal of Molecular Neuroscience, 2008, 34, 9-15.	2.3	8
178	Genetic heterogeneity versus molecular analysis of prion susceptibility in neuroblasma N2a sublines. Archives of Virology, 2008, 153, 1693-1702.	2.1	11
179	Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers. Proteomics - Clinical Applications, 2008, 2, 428-436.	1.6	88
180	A new genetic algorithm in proteomics: Feature selection for SELDI-TOF data. Computational Statistics and Data Analysis, 2008, 52, 4380-4394.	1.2	11

#	Article	IF	Citations
181	Important research questions in allergy and related diseases: nonallergic rhinitis: a GA²LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 842-853.	5.7	158
182	Cell specific differences between human adipose-derived and mesenchymalâ€“stromal cells despite similar differentiation potentials. Experimental Cell Research, 2008, 314, 1575-1584.	2.6	316
183	Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. Biology of the Cell, 2008, 100, 603-618.	2.0	124
184	Trehalose impairs aggregation of PrPSc molecules and protects prion-infected cells against oxidative damage. Biochemical and Biophysical Research Communications, 2008, 374, 44-48.	2.1	76
185	Autoantibody profiling on high-density protein microarrays for biomarker discovery in the cerebrospinal fluid. Journal of Immunological Methods, 2008, 338, 75-78.	1.4	11
186	Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2008, 67, 741-749.	0.9	139
187	Prions Impair Bioaminergic Functions through Serotonin- or Catecholamine-derived Neurotoxins in Neuronal Cells. Journal of Biological Chemistry, 2008, 283, 23782-23790.	3.4	21
188	Cellular pathogenesis in prion diseases. Veterinary Research, 2008, 39, 44.	3.0	20
189	Cyclodextrins Inhibit Replication of Scrapie Prion Protein in Cell Culture. Journal of Virology, 2007, 81, 11195-11207.	3.4	39
190	Proteomics of primary mesenchymal stem cells. Regenerative Medicine, 2006, 1, 511-517.	1.7	21
191	Neural Stem Cell Model for Prion Propagation. Stem Cells, 2006, 24, 2284-2291.	3.2	37
192	Interest of major serum protein removal for Surface-Enhanced Laser Desorption/Ionization - Time Of Flight (SELDI-TOF) proteomic blood profiling. Proteome Science, 2006, 4, 20.	1.7	35
193	The truncated 23-230 form of the prion protein localizes to the nuclei of inducible cell lines independently of its nuclear localization signals and is not cytotoxic. Molecular and Cellular Neurosciences, 2006, 32, 315-323.	2.2	23
194	Retrovirus infection strongly enhances scrapie infectivity release in cell culture. EMBO Journal, 2006, 25, 2674-2685.	7.8	112
195	Comparison between surface and bead-based MALDI profiling technologies using a single bioinformatics algorithm. Clinical Proteomics, 2006, 2, 145-152.	2.1	1
196	A Novel Copperâ€“Hydrogen Peroxide Formulation for Prion Decontamination. Journal of Infectious Diseases, 2006, 194, 865-869.	4.0	22
197	Prion Propagation in Cell Culture. , 2005, 299, 227-234.		8
198	Heat Shock Affects Trafficking of DAX-1 by Inducing Its Rapid and Reversible Cytoplasmic Localization. Endocrine, 2005, 28, 137-144.	2.2	6

#	Article	IF	Citations
199	The scrapie prion protein is present in flotillin-1-positive vesicles in central- but not peripheral-derived neuronal cell lines. European Journal of Neuroscience, 2005, 21, 2063-2072.	2.6	62
200	Biological and Biochemical Characteristics of Prion Strains Conserved in Persistently Infected Cell Cultures. Journal of Virology, 2005, 79, 7104-7112.	3.4	36
201	Screening of 145 Anti-PrP Monoclonal Antibodies for Their Capacity to Inhibit PrPSc Replication in Infected Cells. Journal of Biological Chemistry, 2005, 280, 11247-11258.	3.4	272
202	Elevated plasma cysteinylglycine levels caused by cilastatin-associated antibiotic treatment. Clinical Chemistry and Laboratory Medicine, 2005, 43, 332-4.	2.3	8
203	Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations. Journal of Cell Science, 2004, 117, 5591-5597.	2.0	40
204	Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. Journal of General Virology, 2004, 85, 1791-1799.	2.9	172
205	Scrapie-like prion protein is translocated to the nuclei of infected cells independently of proteasome inhibition and interacts with chromatin. Journal of Cell Science, 2004, 117, 2411-2416.	2.0	78
206	Anti-PrP antibodies block PrPScreplication in prion-infected cell cultures by accelerating PrPCdegradation. Journal of Neurochemistry, 2004, 89, 454-463.	3.9	111
207	Prion protein protects against DNA damage induced by paraquat in cultured cells. Free Radical Biology and Medicine, 2004, 37, 1224-1230.	2.9	47
208	Alpha- and beta- cleavages of the amino-terminus of the cellular prion protein. Biology of the Cell, 2004, 96, 125-132.	2.0	150
209	Prion protein suppresses perturbation of cellular copper homeostasis under oxidative conditions. Biochemical and Biophysical Research Communications, 2004, 313, 850-855.	2.1	38
210	Detection of prion after decontamination procedures: comparative study of standard Western blot, filter retention and scrapie-cell assay. Journal of Hospital Infection, 2004, 57, 156-161.	2.9	17
211	Determination of plasma amino acids by fluorescent derivatization and reversed-phase liquid chromatographic separation. Clinical Laboratory, 2004, 50, 153-8.	0.5	5
212	Prion-like protein Doppel expression is not modified in scrapie-infected cells and in the brains of patients with Creutzfeldt-Jakob disease. FEBS Letters, 2003, 536, 61-65.	2.8	18
213	Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Molecular and Cellular Neurosciences, 2003, 22, 227-233.	2.2	164
214	Structure-function analysis reveals the molecular determinants of the impaired biological function of DAX-1 mutants in AHC patients. Human Molecular Genetics, 2003, 12, 1063-1072.	2.9	44
215	Prion propagation in cultured cells. British Medical Bulletin, 2003, 66, 87-97.	6.9	77
216	Prion Infection Impairs Copper Binding of Cultured Cells. Journal of Biological Chemistry, 2003, 278, 14595-14598.	3.4	54

#	Article	IF	Citations
217	Expression of Prion Protein Increases Cellular Copper Binding and Antioxidant Enzyme Activities but Not Copper Delivery. Journal of Biological Chemistry, 2003, 278, 9064-9072.	3.4	173
218	From Chemical Drug to Immunotherapy: New Approaches for the Treatment of Prion Diseases. Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents, 2003, 3, 199-205.	0.2	1
219	Filipin Prevents Pathological Prion Protein Accumulation by Reducing Endocytosis and Inducing Cellular PrP Release. Journal of Biological Chemistry, 2002, 277, 25457-25464.	3.4	126
220	Stimulation of PrPC Retrograde Transport toward the Endoplasmic Reticulum Increases Accumulation of PrPSc in Prion-infected Cells. Journal of Biological Chemistry, 2002, 277, 38972-38977.	3.4	98
221	X-linked adrenal hypoplasia congenita is caused by abnormal nuclear localization of the DAX-1 protein. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8225-8230.	7.1	46
222	The Human â€œPrion-likeâ€•Protein Doppel Is Expressed in Both Sertoli Cells and Spermatozoa. Journal of Biological Chemistry, 2002, 277, 43071-43078.	3.4	75
223	PrP Expression and Replication by Schwann Cells: Implications in Prion Spreading. Journal of Virology, 2002, 76, 2434-2439.	3.4	72
224	PrP-dependent cell adhesion in N2a neuroblastoma cells. FEBS Letters, 2002, 514, 159-162.	2.8	81
225	BSE infection of the small short-lived primate Microcebus murinus. Comptes Rendus - Biologies, 2002, 325, 67-74.	0.2	10
226	From stem cells to prion signalling. Comptes Rendus - Biologies, 2002, 325, 9-15.	0.2	2
227	Oxidative stress and the prion protein in transmissible spongiform encephalopathies. Brain Research Reviews, 2002, 38, 328-339.	9.0	167
228	La ProtÃ©ine du Prion. SociÃ©tÃ© De Biologie Journal, 2002, 196, 309-312.	0.3	2
229	Metal ions and prion diseases. Current Opinion in Chemical Biology, 2002, 6, 187-192.	6.1	105
230	Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. Transfusion, 2002, 42, 513-516.	1.6	52
231	Cell Culture Models of Transmissible Spongiform Encephalopathies. Biochemical and Biophysical Research Communications, 2001, 289, 311-316.	2.1	28
232	Effect of Amphotericin B on Wild-Type and Mutated Prion Proteins in Cultured Cells. Journal of Neurochemistry, 2001, 74, 754-762.	3.9	25
233	Effect of Congo Red on Wild-Type and Mutated Prion Proteins in Cultured Cells. Journal of Neurochemistry, 2001, 74, 222-230.	3.9	35
234	Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 4055-4059.	7.1	203

#	Article	IF	Citations
235	Cleavage of the Amino Terminus of the Prion Protein by Reactive Oxygen Species. Journal of Biological Chemistry, 2001, 276, 2286-2291.	3.4	154
236	Glycosylation of prions and its effects on protein conformation relevant to amino acid mutations. Journal of Molecular Graphics and Modelling, 2000, 18, 126-134.	2.4	22
237	Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion Protein in Infected Cultures. Journal of Virology, 2000, 74, 3135-3140.	3.4	112
238	Successful Transmission of Three Mouse-Adapted Scrapie Strains to Murine Neuroblastoma Cell Lines Overexpressing Wild-Type Mouse Prion Protein. Journal of Virology, 2000, 74, 320-325.	3.4	220
239	Prion infection impairs the cellular response to oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13937-13942.	7.1	203
240	Phorbol Ester-regulated Cleavage of Normal Prion Protein in HEK293 Human Cells and Murine Neurons. Journal of Biological Chemistry, 2000, 275, 35612-35616.	3.4	98
241	Signal Transduction Through Prion Protein. Science, 2000, 289, 1925-1928.	12.6	701
242	Trafficking of the cellular isoform of the prion protein. Biomedicine and Pharmacotherapy, 1999, 53, 39-46.	5.6	19
243	Familial Prion Diseases Modeled in Cell Culture. , 1998, , 87-98.		0
244	Blockade of Glycosylation Promotes Acquistion of Scrapie-like Properties by the Prion Protein in Cultured Cells. Journal of Biological Chemistry, 1997, 272, 21479-21487.	3.4	163
245	Evidence for a Six-transmembrane Domain Structure of Presenilin 1. Journal of Biological Chemistry, 1997, 272, 12047-12051.	3.4	143
246	Identification of Intermediate Steps in the Conversion of a Mutant Prion Protein to a Scrapie-like Form in Cultured Cells. Journal of Biological Chemistry, 1997, 272, 11604-11612.	3.4	84
247	A wild-type prion protein does not acquire properties of the scrapie isoform when coexpressed with a mutant prion protein in cultured cells. Molecular Brain Research, 1997, 52, 139-145.	2.3	13
248	Two mutant prion proteins expressed in cultured cells acquire biochemical properties reminiscent of the scrapie isoform.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 5610-5614.	7.1	98
249	Mutant and Infectious Prion Proteins Display Common Biochemical Properties in Cultured Cells. Journal of Biological Chemistry, 1996, 271, 1633-1637.	3.4	128
250	Le rÃ1e de la protÃ©ine du prion dans les encÃ©phalopathies spongiformes transmissibles humaines.. Medecine/Sciences, 1996, 12, 949.	0.2	4
251	Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells. Journal of Biological Chemistry, 1995, 270, 30221-30229.	3.4	538
252	A Mutant Prion Protein Displays an Aberrant Membrane Association When Expressed in Cultured Cells. Journal of Biological Chemistry, 1995, 270, 24589-24597.	3.4	141

#	Article	IF	Citations
253	An endogenous lectin and its glycoprotein ligands are triggering basal and axon-induced Schwann cell proliferation. Glycobiology, 1995, 5, 371-383.	2.5	13
254	Differential expression of an endogenous mannose-binding protein R1 during muscle development and regeneration delineating its role in myoblast fusion. Glycobiology, 1994, 4, 23-38.	2.5	9
255	Presence of anti-CSL antibodies in the cerebrospinal fluid of patients: A sensitive and specific test in the diagnosis of multiple sclerosis. Journal of Neuroimmunology, 1994, 52, 175-182.	2.3	14
256	Cellular processing of normal and mutant mammalian prion proteins. Neurobiology of Aging, 1994, 15, S87-S88.	3.1	29
257	Neurite outgrowth of neurons of rat dorsal root ganglia induced by new neurotrophic substances with guanidine group. Neuroscience Letters, 1993, 152, 57-60.	2.1	8
258	Lesion-induced re-expression of neonatal recognition molecules in adult rat cerebellum. Brain Research Bulletin, 1993, 30, 515-521.	3.0	18
259	Cerebellar Lectins. International Review of Cytology, 1992, 135, 123-154.	6.2	7
260	Cerebrospinal fluid anti-cerebellar soluble lectin antibodies in human immunodeficiency virus type 1 infection. Journal of Neuroimmunology, 1992, 36, 245-249.	2.3	10
261	Glycoproteins and lectins in cell adhesion and cell recognition processes. The Histochemical Journal, 1992, 24, 791-804.	0.6	42
262	Endogenous Lectin Cerebellar Soluble Lectin Involved in Myelination Is Absent from Nonmyelinating Schwann Cells. Journal of Neurochemistry, 1992, 58, 1768-1772.	3.9	10
263	Brain Lectins:Structure and Function.. Trends in Glycoscience and Glycotechnology, 1992, 4, 415-426.	0.1	3
264	An endogenous lectin and one of its neuronal glycoprotein ligands are involved in contact guidance of neuron migration.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 6455-6459.	7.1	46
265	Antibodies to cerebellar soluble lectin CSL in multiple sclerosis. Lancet, The, 1990, 335, 1482-1484.	13.7	25
266	Location of a transiently expressed glycoprotein in developing cerebellum delineating its possible ontogenetic roles. Neuroscience, 1989, 33, 111-124.	2.3	42
267	Ex Vivo Transmission of Mouse-Adapted Prion Strains to N2a and GT1-7 Cell Lines. , 0, , 679-686.		2
268	Comparison of Hydrophobic, Lipophilic and Immunodepletion Pre- Fractionation Methods for Label-Free LC-MS/MS Identification of Biomarkers in Human Cerebrospinal Fluid. Journal of Proteomics and Bioinformatics, 0, s5, .	0.4	2